PreclinicalShort bioregulator peptide

Bronchogen

Ala-Glu-Asp-Leu (AEDL)

Common dose: ~1–2 mg daily for 10–20 days
Cycle: 2-week course, about every 5 months
Vial sizes: 10, 20 mg
Typical draw: 10 units20 mg with 2 mL, 1 mg

A synthetic four-amino-acid peptide (Ala-Glu-Asp-Leu) from the Russian bioregulator family, promoted for the lungs and airways. In rats with lung damage from nitrogen dioxide it reduced airway inflammation and remodeling.

Evidence. Two rat studies of COPD-like lung damage from a St. Petersburg pulmonology group, plus cell and DNA-binding work from Vladimir Khavinson’s group and its partners. No human study has been published. Russia registers it only as a dietary supplement, not a medicine.

What it’s used for

None of these uses is approved, and none has been tested in people. Here is what each claim rests on.

Bronchitis and COPD: AnimalUnproven in people: in rats with COPD-like damage from nitrogen dioxide, a month of treatment reduced airway remodeling, emphysema and inflammation (Kuzubova 2015). No human study has been published.
Pneumonia and lung injury: AnimalUnproven: its developers say it helped animal models of bacterial lung inflammation, fibrosis and toxic lung damage, in studies not found in PubMed. No human data.
Lung and airway aging: AnimalUnproven: in aging cultures of human embryonic bronchial cells it raised cell-renewal markers and airway-lining genes (Khavinson 2014). It hasn’t been tested in older people or smokers.
Asthma: No studyUnproven: no study has tested it in asthma, in people or animals.

Animal: cell or animal studies only. No study: nothing published supports it.

Every compound’s uses, by body system: evidence map, and by condition: conditions A to Z.

Status

Approval: Not approved as a drug in the US, the EU or anywhere else. In Russia it’s registered as a dietary supplement (capsules), not a medicine.
US compounding: Not nominated: it isn’t on FDA’s 503A or 503B bulk lists or in any of FDA’s bulk-substance categories (503A categories updated May 14, 2026).
European Union: No marketing authorization; no medicine containing Bronchogen is approved anywhere.
United Kingdom: No marketing authorization (MHRA).
Canada: No marketing authorization; no Bronchogen product is listed in Health Canada’s Drug Product Database.
Australia: No marketing authorization. Bronchogen isn’t named in the Poisons Standard (October 2026).
Sport (WADA 2026): Likely banned in sportNot named on WADA’s 2026 list. A Russian supplement registration isn’t an approval for human therapeutic use, so S0 (non-approved substances) applies, at all times.

Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.

How it works

No target for Bronchogen has been identified. Its developers propose that short peptides enter cells and bind DNA to change gene activity. In cultured human embryonic bronchial cells it raised markers of cell renewal and switched on genes for airway-lining cells and for mucus and surfactant proteins, most strongly in aging cultures. In rats with COPD-like lung damage, a month of treatment reduced inflammation and restored the airway lining.

AnimalMainly from cell and animal studies; not shown in people.

Not known

Whether it reaches the lungs intact after an injection or a capsule, and whether the rat and cell effects happen in people, is unknown. No human study has been published.

Protocol

Community

Injected: 1–2 mg once daily for 10–20 days in most guides; one uses 100–500 mcg a day. No human dosing study exists.

Community

By mouth: the Russian supplement’s directions are 1–2 capsules (100 mcg of peptide each) 1–2× daily with meals for 1 month, repeated after 4–6 months. A supplement label, not a drug approval.

Frequency: Once daily during a course
Route: Subcutaneous injection (community); capsules by mouth (Russian supplement)
Cycle: 10–20 day injected courses, repeated every few months; the Russian capsules run for a month, repeated after 4–6 months.
2-week course, about every 5 months, shown over 26 weeks

Common protocols

The ways Bronchogen is most often run, each tagged with where it comes from.

Injected course

Community

Dose: 1–2 mg
How often: Once daily
How long: 10–20 days

Where most injection guides overlap; one uses 100–500 mcg a day instead. Never tested in people.

Draw 10–20 units20 mg + 2 mL

Russian capsules

Community

Dose: 1–2 capsules (100 mcg of peptide each)
How often: 1–2 times daily with meals
How long: 1 month, repeated after 4–6 months

The Russian supplement maker’s directions. A registered supplement, not an approved medicine.

Taking it

Where it goes

Subcutaneous in the abdomen or thigh, rotating sites (community). In Russia it’s taken as capsules by mouth. Neither route has been tested in people.

If you miss a dose

No published guidance. Resume the next day and don’t double up.

Missed doses for every compound

What to expect

During a course
Guides promote it for easier breathing, less cough and faster recovery after chest infections. No human study has measured any of these.
Community
After 1 month (rats)
In rats with COPD-like damage from 60 days of nitrogen dioxide, a month of treatment reduced airway remodeling, emphysema and neutrophil inflammation.
Animal

Side effects and what to do

Injection-site soreness or redness

Usually mild; rotate sites. Spreading redness, heat or pus means see a doctor.

No side-effect data in people

No human study exists; the Russian supplement lists no side effects, but that isn’t trial evidence. Report anything new to a doctor.

Allergic reaction (possible with any peptide product)

Stop and get emergency care for hives, facial swelling or trouble breathing.

Stop and get medical help

Stop and get medical help for hives, swelling of the face or throat, trouble breathing, or a hot, spreading or pus-filled injection site. No study supports using it in place of prescribed asthma or COPD treatment.

Can it cause …?

There are almost no human safety data for Bronchogen, so most of these can’t be answered either way.

Acne, rash or skin changes: No dataNo human data. Redness or soreness where it’s injected is possible with any injected peptide.
Cancer risk: PrecautionNo cancer studies exist. In human bronchial cell cultures it raised markers of cell division and survival (Ki67, Mcl-1); effects on tumors are unknown.
TirednessHeadacheNausea or vomitingDiarrhea or constipationDizzinessTrouble sleepingHair lossWater retention or swellingJoint or muscle painAnxiety, low mood or irritabilityLow or high blood sugarFast heartbeat or blood pressure changesMore hunger: No dataNo human data: no study of Bronchogen in people has been published, so side effects are unknown.
Liver strainKidney problems: No dataNo human data, and no animal toxicity study has been published.

Precaution: a concern that follows from how it works or from a related drug, not measured. No data: no human safety data. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.

Who should avoid it

No product label covers Bronchogen, so these come from human studies and from precautions based on how it works. Most important first.

Anyone with active or past cancer: PrecautionIn human bronchial cell cultures it raised Ki67 and Mcl-1, markers of cell division and cell survival. No study has tested whether it affects tumors.
Pregnancy or breastfeeding: PrecautionNo human safety data exist, and the Russian capsule supplement lists both as contraindications.
People treating asthma or COPD: PrecautionIt has never been tested in people with lung disease; using it in place of prescribed treatment could leave the disease undertreated.
Anyone relying on product quality: PrecautionIt isn’t an approved drug anywhere, so vials have no regulated standard for identity, purity or sterility; cartalax vials have been sold labeled AEDL.

Interactions

No interaction studies have been published, and no product label lists any.

Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.

Special situations

What’s known about pregnancy, breastfeeding, kidney and liver problems, age and surgery. Where nothing has been studied, the row says so.

Pregnancy: PrecautionNo human or animal pregnancy data. The Russian capsule supplement lists pregnancy as a contraindication.
Breastfeeding: PrecautionNo human data. The Russian capsule supplement says to stop breastfeeding while taking it.
Kidney problems: PrecautionNot studied in people with kidney disease; how the body clears it is unknown.
Liver problems: PrecautionNot studied in people with liver disease; how the body breaks it down is unknown.
Older adults: PrecautionNo study has given it to older people. Claims for aging lungs rest on aging cell cultures and old-rat tissue.
Children and teens: PrecautionNot studied in anyone under 18, and not approved for any age. The Russian supplement directions cover adults only.
Surgery and anesthesia: PrecautionNo data; tell the surgical team about any injected compound or supplement.

Precaution: not studied, so the caution follows from how it works or from a related drug. Ages are given as approved or studied; this site never gives doses for children. Across every compound: pregnancy, breastfeeding, kidney disease, liver disease, older adults and surgery.

Tracking and pairing

Worth tracking

No established labs or checks.

Often paired with

Chonluten
Paired in some lung-focused bioregulator stacks. No study has tested the combination.

Human studies

No published human studies of Bronchogen turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.

Trials under way

No ongoing trial of Bronchogen is registered, and none has finished recently without publishing its results. Checked on ClinicalTrials.gov, October 7, 2026. Every compound: trials under way.

Limits of the evidence

Bronchogen has no published human study. The evidence is two rat studies of COPD-like lung damage from one St. Petersburg pulmonology group, cell and DNA-binding work from Khavinson’s group and partners, and studies in tobacco-plant roots. The developers’ papers even disagree on its sequence (AEDL or ADEL). Injected and oral doses, long-term safety and product purity are untested in people.

Mixing your vial

Vial	Water	Common dose	Draw	Strength	Action
10 mg	2 mL	1 mg	20 units (0.20 mL)	5 mg/mL
20 mg	2 mL	1 mg	10 units (0.10 mL)	10 mg/mL

In Russia it’s sold as dietary supplement capsules holding 100 mcg of the peptide complex, not as vials. Check that vials read Ala-Glu-Asp-Leu (AEDL): cartalax (Ala-Glu-Asp) differs by one amino acid and has been sold labeled AEDL.

Dose chart

Syringe units for common doses at different water volumes. Select a cell to open it in the calculator.

Dose	Water added
Dose	1 mL	2 mL	3 mL
0.1 mg
0.2 mg
0.3 mg
0.5 mg
0.6 mg
1 mg
2 mg

U-100 insulin syringe: 100 units is 1 mL. Draws over 100 units show in mL. Faded values are under 2 units, which is hard to measure. Check that your vial holds the larger volumes.

Datasheet

Half-life: No reliable value has been published.
Type: Peptide, 4 amino acids
Molecular weight: 446.5 g/mol
Formula: C₁₈H₃₀N₄O₉
Sequence: AEDL
Storage before use: Freezer (−20 °C) for long-term storage; fridge is fine for short periods.
After mixing or opening: Refrigerate (2–8 °C) after mixing and use within about 4 weeks.

Molecule: PubChem CID 11690869; sequence per Khavinson 2012 (PMID 22808515) and Fedoreyeva 2011 (PMID 22117547)
Storage: Community Common practice for research peptide vials; no approved product label exists

Every compound side by side: the half-life chart and the storage chart.

Identifiers

CAS number: 857267-12-0 (as listed in PubChem)
UNII (FDA): None assigned
PubChem CID: 11690869
ATC code: None assigned
Development codes: None; also written AEDL (Ala-Glu-Asp-Leu)
Brand names: Bronchogen (Russian dietary supplement capsules); no medicine contains it
First described: From Vladimir Khavinson’s St. Petersburg bioregulator group; the earliest PubMed record naming it dates from 2006.

Every compound’s numbers: the identifiers table.

Product form and quality

A four-amino-acid peptide, Ala-Glu-Asp-Leu (AEDL), though two of the developers’ papers write Ala-Asp-Glu-Leu. Cartalax (Ala-Glu-Asp) differs by one amino acid. Russian capsules hold 100 mcg of peptide complex; research vials have no regulated standard.

Cautions

No published human study, so there are no human safety or dosing data.
The evidence is two rat studies plus cell and DNA work, nearly all from Russian and Georgian labs.
Cartalax (AED) and Bronchogen (AEDL) differ by one amino acid and have been mixed up on vial labels.

Questions

What is Bronchogen?

How does Bronchogen work?

Is Bronchogen FDA-approved?

Not approved as a drug in the US, the EU or anywhere else. In Russia it’s registered as a dietary supplement (capsules), not a medicine. Not nominated: it isn’t on FDA’s 503A or 503B bulk lists or in any of FDA’s bulk-substance categories (503A categories updated May 14, 2026).

What is the usual Bronchogen dose?

From community reports, not established: Injected: 1–2 mg once daily for 10–20 days in most guides; one uses 100–500 mcg a day. No human dosing study exists. By mouth: the Russian supplement’s directions are 1–2 capsules (100 mcg of peptide each) 1–2× daily with meals for 1 month, repeated after 4–6 months. A supplement label, not a drug approval. These are the amounts sources reference, not recommendations.

How much water do I mix Bronchogen with?

There’s no single right amount, because the water only sets the strength. With 2 mL of bacteriostatic water in a 20 mg vial, the strength is 10 mg/mL, so 1 mg is 10 units on a U-100 insulin syringe. More water makes small doses easier to measure. The dose chart above shows other volumes.

Who should avoid Bronchogen?

No product label covers Bronchogen, so these come from human studies and from precautions based on how it works. Anyone with active or past cancer: In human bronchial cell cultures it raised Ki67 and Mcl-1, markers of cell division and cell survival. No study has tested whether it affects tumors. Pregnancy or breastfeeding: No human safety data exist, and the Russian capsule supplement lists both as contraindications. People treating asthma or COPD: It has never been tested in people with lung disease; using it in place of prescribed treatment could leave the disease undertreated. The “Who should avoid it” section lists 1 more group.

How should Bronchogen be stored?

Before mixing: Freezer (−20 °C) for long-term storage; fridge is fine for short periods. Refrigerate (2–8 °C) after mixing and use within about 4 weeks. This is common practice; no product label covers it.

Is Bronchogen banned in sport?

Probably. Not named on WADA’s 2026 list. A Russian supplement registration isn’t an approval for human therapeutic use, so S0 (non-approved substances) applies, at all times.

Has Bronchogen been studied in people?

No published human studies turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.

How long has Bronchogen been studied in people?

No data No human studies: no study of Bronchogen in people has been published.

Does Bronchogen come in other forms, like a pill or nasal spray?

No data Sold in Russia as capsules taken by mouth and elsewhere as vials injected under the skin. Neither route has been tested in people; rat studies gave it for a month.

Can you drink alcohol while taking Bronchogen?

No study No data. No study has looked at Bronchogen and alcohol together.

Can Bronchogen be taken with semaglutide or tirzepatide?

No study No study has combined them. No interaction is known, but none has been looked for.

What happens if you take too much Bronchogen?

No data There’s no drug label, no overdose data and no human dosing study. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.

Sources

Kuzubova et al., Bronchogen and the bronchial lining in rats with obstructive lung disease (Bull Exp Biol Med 2015) PMID 26468022
Titova et al., anti-inflammatory and regenerative effect of Bronchogen in a rat model of obstructive lung disease (Ross Fiziol Zh 2017, in Russian) PMID 30199201
Khavinson et al., peptide regulation of gene expression and protein synthesis in bronchial epithelium (Lung 2014) PMID 25015171
Khavinson et al., tissue-specific peptides, including bronchogen (Ala-Glu-Asp-Leu), and cell differentiation (Bull Exp Biol Med 2012) PMID 22808515
Bronchogen dietary supplement directions: composition, dosing, contraindications and storage (RLS Russia entry; instructions approved October 17, 2012)

For the protocol details

Bronchogen dietary supplement directions (RLS Russia entry; instructions approved October 17, 2012)

For how it works, who should avoid it and the limits of the evidence

Fedoreyeva et al., the peptide AEDL and tobacco-plant root growth under salinity (Plants 2022) PMID 35631778
Bronchogen dietary supplement directions, contraindications (RLS Russia entry; instructions approved October 17, 2012)

For uses, the side-effect questions, special situations, trials, identifiers and status outside the US

Monaselidze et al., the peptide bronchogen (written Ala-Asp-Glu-Leu) and DNA thermostability (Bull Exp Biol Med 2011) PMID 21240358
Zakutskii et al., cardiogen, bronchogen, prostamax and pancragen in tissue cultures from young and old rats (Adv Gerontol 2006, in Russian) PMID 17152728
Bronchogen dietary supplement directions: composition, dosing, contraindications, storage (RLS Russia entry; instructions approved October 17, 2012)
ClinicalTrials.gov search for bronchogen (October 8, 2026); PubChem CID 11690869; FDA Global Substance Registration System search (no record)
Health Canada Drug Product Database search (October 8, 2026) and Australian Poisons Standard, October 2026 (F2026L01327)

Doses tagged Community come from public dosing guides and user reports, checked against at least two of them. Those sites aren’t named here because many of them sell peptides or earn commissions on them.

By Vial Guide editorsLast reviewed October 7, 2026

How we review